Literature DB >> 29055182

Computational drug repositioning for rare diseases in the era of precision medicine.

Brian Delavan1, Ruth Roberts2, Ruili Huang3, Wenjun Bao4, Weida Tong5, Zhichao Liu6.   

Abstract

There are tremendous unmet needs in drug development for rare diseases. Computational drug repositioning is a promising approach and has been successfully applied to the development of treatments for diseases. However, how to utilize this knowledge and effectively conduct and implement computational drug repositioning approaches for rare disease therapies is still an open issue. Here, we focus on the means of utilizing accumulated genomic data for accelerating and facilitating drug repositioning for rare diseases. First, we summarize the current genome landscape of rare diseases. Second, we propose several promising bioinformatics approaches and pipelines for computational drug repositioning for rare diseases. Finally, we discuss recent regulatory incentives and other enablers in rare disease drug development and outline the remaining challenges. Published by Elsevier Ltd.

Mesh:

Substances:

Year:  2017        PMID: 29055182     DOI: 10.1016/j.drudis.2017.10.009

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  18 in total

1.  Repurposing the Dihydropyridine Calcium Channel Inhibitor Nicardipine as a Nav1.8 Inhibitor In Vivo for Pitt Hopkins Syndrome.

Authors:  Sean Ekins; Ana C Puhl; Audrey Davidow
Journal:  Pharm Res       Date:  2020-06-11       Impact factor: 4.200

2.  Topological network measures for drug repositioning.

Authors:  Apurva Badkas; Sébastien De Landtsheer; Thomas Sauter
Journal:  Brief Bioinform       Date:  2021-07-20       Impact factor: 11.622

3.  Use of big data in drug development for precision medicine: an update.

Authors:  Tongqi Qian; Shijia Zhu; Yujin Hoshida
Journal:  Expert Rev Precis Med Drug Dev       Date:  2019-05-20

Review 4.  Toxicodynamics of Mycotoxins in the Framework of Food Risk Assessment-An In Silico Perspective.

Authors:  Luca Dellafiora; Chiara Dall'Asta; Gianni Galaverna
Journal:  Toxins (Basel)       Date:  2018-01-23       Impact factor: 4.546

5.  Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.

Authors:  William C Reisdorf; Qing Xie; Xin Zeng; Wensheng Xie; Neetu Rajpal; Bao Hoang; Mark E Burgert; Vinod Kumar; Mark R Hurle; Deepak K Rajpal; Sarah O'Donnell; Thomas T MacDonald; Anna Vossenkämper; Lin Wang; Mike Reilly; Bart J Votta; Yolanda Sanchez; Pankaj Agarwal
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

6.  Repurposing a rare opportunity: a brief insight into how implicit bias towards biomedicine impacts the care received by patients with a rare illness.

Authors:  Logan Zane John Williams
Journal:  Orphanet J Rare Dis       Date:  2019-02-28       Impact factor: 4.123

7.  The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force.

Authors:  Noel T Southall; Madhusudan Natarajan; Lilian Pek Lian Lau; Anneliene Hechtelt Jonker; Benoît Deprez; Tim Guilliams; Lawrence Hunter; Carin Ma Rademaker; Virginie Hivert; Diego Ardigò
Journal:  Orphanet J Rare Dis       Date:  2019-10-15       Impact factor: 4.123

Review 8.  A scoping review and proposed workflow for multi-omic rare disease research.

Authors:  Katie Kerr; Helen McAneney; Laura J Smyth; Caitlin Bailie; Shane McKee; Amy Jayne McKnight
Journal:  Orphanet J Rare Dis       Date:  2020-04-28       Impact factor: 4.123

Review 9.  The Contribution of Clinical Pharmacologists in Precision Medicine: An Opportunity for Health Care Improvement.

Authors:  Davide Grisafi; Alessandro Ceschi; Veronica Avalos Clerici; Francesco Scaglione
Journal:  Curr Ther Res Clin Exp       Date:  2021-04-01

10.  A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome.

Authors:  Karla Misselbeck; Silvia Parolo; Francesca Lorenzini; Valeria Savoca; Lorena Leonardelli; Pranami Bora; Melissa J Morine; Maria Caterina Mione; Enrico Domenici; Corrado Priami
Journal:  Nat Commun       Date:  2019-11-18       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.